Navigation Links
Barr Reports GAAP Earnings of $1.18 Per Share for 2007 and $0.30 Per Share for the Fourth Quarter; Adjusted Earnings Were $3.16 Per Share for 2007 and $0.79 Per Share for the Fourth Quarter
Date:2/28/2008

profits from sales of fexofenadine hydrochloride tablets from Teva, which began in September 2005, and lower income from the royalty earned under its April 2005 agreements with Kos Pharmaceuticals relating to the Niaspan(R) and Advicor(R) cholesterol lowering agents. These declines were partially offset by an increase in royalties and other fees received under the Company's agreements with Shire plc.

Other Revenue

Other revenue primarily includes revenue from non-core operations acquired in connection with the PLIVA acquisition, including the diagnostic, disinfectants, dialysis and infusions business. Other revenue totaled $45 million for calendar 2007 and $12 million for the fourth quarter of 2007.

Margins

Generic: Margins in the generic segment were 47% for both the quarter and year ended December 31, 2007.

Proprietary: Margins in the proprietary segment for the quarter and year ended December 31, 2007 were 55% and 68%, respectively. Proprietary margins for the fourth quarter ended December 31, 2007 were negatively impacted by a $13.7 million, or $0.08 per share, charge related to a product royalty contingency agreement for the Company's Cenestin(R) product.

Update on R&D Activities

Research and development investment for the quarter and year ended December 31, 2007 totaled $62 million and $248 million, respectively.

Generic Products

During 2007, the Company filed 30 Abbreviated New Drug Applications (ANDAs), resulting in approximately 70 ANDAs, including tentatively approved applications pending at the U.S. Food and Drug Administration (FDA) at the end of the year. These ANDAs target branded pharmaceutical products with an estimated $29 billion in annual sales. The Company also filed 224 product registrations, representing 65 molecules with regulatory bodies in Europe and in the ROW during 2007, resulting in 287 product registrations, representing 90 molecules pending with regulatory bodies in Europe
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. QMed, Inc. Reports July Medicare SNP Enrollments
3. Phlo Affiliate Reports Expanded Coverage to Oregon Border
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Avitar Reports Third Quarter Financial Results for Fiscal 2007
8. Response Genetics Reports Second Quarter 2007 Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Transgenomic, Inc. Reports Second Quarter 2007 Results
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Spin-charge converters are important devices in spintronics, an ... charge of electrons but also on their spin ... transformation of electric into magnetic signals and vice ... Sinova from the Institute of Physics at Johannes ... the UK, Prague, and Japan, has for the ...
(Date:8/28/2014)... 28, 2014 The ability for organizations ... that will allow individuals to perform at the highest ... for employers looking to compete in this post–recession era. ... this trend, as the sector increasingly focuses on the ... which will have real results on the organization's development ...
(Date:8/28/2014)... Aug. 28, 2014   SunTrust Robinson Humphrey ... veterans to its equity research team in biotechnology ... expansion in equity research demonstrates our commitment to ... to enhance their investment decision making," said ... "We continue to make significant investments in differentiated ...
(Date:8/28/2014)... 28, 2014  Armetheon, Inc. ( www.armetheon.com ), ... to late-stage cardiovascular drug candidates, today announced that ... round of financing. The Series A round was ... with participation from investors that included Atheneos Capital ... Larry Hsu , the founder of Impax ...
Breaking Biology Technology:A new, tunable device for spintronics 2A new, tunable device for spintronics 3Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3
... CARMEL, Israel, March 19 InSightec Ltd. reported,today that it ... its existing investors. , Elbit Imaging ... on March,18, 2009. Additional US$7.5M would be invested no later ... , The investment will take the ...
... Company estimates sales of pixantrone, if approved, could potentially ... Philips, President of Cell Therapeutics, Inc. (CTI) (NASDAQ and ... the 8th Annual WBBA Invest Northwest Conference on Wednesday, ... CTI,s pixantrone program for treatment of aggressive relapsed non-Hodgkin,s ...
... Team will sail to Baltic, Black and Mediterranean ... funded by local San Diego supporters Beyster Family ... and othersSAN DIEGO, March 18, The J. ... of a new Sorcerer II Expedition--the J. Robert ...
Cached Biology Technology:InSightec Ltd. Announces US$15 Million Investment Round 2InSightec Ltd. Announces US$15 Million Investment Round 3Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference 2Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference 3Venter Institute Launches the J. Robert Beyster and Life Technologies 2009-2010 Research Voyage of the Sorcerer II Expedition 2Venter Institute Launches the J. Robert Beyster and Life Technologies 2009-2010 Research Voyage of the Sorcerer II Expedition 3Venter Institute Launches the J. Robert Beyster and Life Technologies 2009-2010 Research Voyage of the Sorcerer II Expedition 4Venter Institute Launches the J. Robert Beyster and Life Technologies 2009-2010 Research Voyage of the Sorcerer II Expedition 5
(Date:8/28/2014)... that could positively impact the global battle ... thanks to researchers in Penn State,s College ... made from the seaweed-derived food ingredient carrageenan ... provides a woman-initiated, drug-delivery vehicle that can ... infections during unprotected heterosexual intercourse, the researchers ...
(Date:8/28/2014)... for measuring and imaging how quickly blood flows in ... how drug abuse affects the brain, which may aid ... to better treatment options for recovering drug addicts. The ... Stony Brook University in New York, USA and the ... The Optical Society,s (OSA) open-access journal Biomedical ...
(Date:8/28/2014)... German . Cars, ... help of sophisticated assembly lines. Mobile assembly carriers, on to ... these assembly lines. In the case of a car body, ... in a precise spatial and chronological sequence, resulting in a ... creation of such an assembly line at molecular level has ...
Breaking Biology News(10 mins):Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 3This is your brain's blood vessels on drugs 2This is your brain's blood vessels on drugs 3Nanoscale assembly line 2Nanoscale assembly line 3
... years, researchers have identified thousands of cell protein ... that occur within cells of various organisms ... information will be critical to understanding the basic ... these processes contribute to cancer. Unfortunately, the ...
... Scientists have discovered a new way for bacteria ... finding that raises the unsettling possibility that bacterial swapping ... common than previously imagined. , In a laboratory experiment, ... Staphylococcus aureus, a notorious bacterium that causes toxic shock ...
... Journal of the American Dietetic Association features research studies ... why sack lunches may not always meet the nutritional needs ... influences diets of young adults. Packing a Lunch ... Approximately 13 million children in the United States eat three ...
Cached Biology News:Studies offer guide as protein interaction mapping comes of age 2Studies offer guide as protein interaction mapping comes of age 3Studies offer guide as protein interaction mapping comes of age 4NYU scientists discover dangerous new method for bacterial toxin transfer 2NYU scientists discover dangerous new method for bacterial toxin transfer 3NYU scientists discover dangerous new method for bacterial toxin transfer 4News from the January 2009 Journal of the American Dietetic Association 2
Liquid. 50 μg/ml in PBS, pH 7.4. PROTECT FROM LIGHT. A convenient form of propidium iodide useful for flow cytometry studies. RTECS SF7949600, CAS 25535-16-4, M.W. 668.4. ...
... Kit contains a green fluorescent-labeled inhibitor, FAM-VAD-FMK, ... valylalanylaspartic acid (VAD) fluoromethyl ketone (FMK), a ... added to a population of cells, the ... covalently binds to a reactive cysteine residue ...
Lyophilized solid. Suitable for evaluating functional activity of human complement components and for other research requiring a high level of hemolytic activity. ...
... VersArray ChipWriter Pro system, 220-240 V, uses ... proteins, oligonucleotides, carbohydrates, lipids, and other biomolecules ... applications. This system can generate high-density arrays ... slide or greater than 57,000 spots per ...
Biology Products: